IMPACT OF TUBERCULOSIS SCREENING ON CLINICAL DECISION-MAKING IN PEDIATRIC PATIENTS RECEIVING BIOLOGIC THERAPY: A SINGLE-CENTER REAL-WORLD STUDY
Eskisehir Medical Journal, Eskisehir City Hospital · 30.05.2026
DOI: 10.48176/esmj.2026.256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eskisehir Medical Journal, Eskisehir City Hospital, online erschienen am 30.05.2026. Verfasst von Sema Nur Taskin und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Children receiving biologic agents for rheumatic diseases are at increased risk for tuberculosis (TB) due to immunosuppression. However, variation exists among guidelines regarding screening methods and frequency. This study evaluated the impact of tuberculosis screening on clinical decision-making before biologic therapy in pediatric rheumatology practice.
Methods
This retrospective single-center study included pediatric patients who initiated biologic therapy between August 2023 and December 2025. All patients underwent pre-treatment screening with clinical evaluation, tuberculin skin test (TST), interferon-gamma release assay (IGRA), and chest radiography. Screening was repeated regularly during follow-up. Agreement between TST and IGRA results was assessed using Cohen’s kappa coefficient.
Results
Sixty-two patients (median age 15 years; 53.2% female) were evaluated. Most had juvenile idiopathic arthritis and received anti-TNF therapy. Isoniazid (INH) prophylaxis was initiated in four patients. One patient developed active tuberculosis despite prophylaxis and biologic therapy was discontinued. Treatment was postponed in one patient due to incomplete vaccination. Isolated IGRA positivity was detected in two patients. Complete agreement between TST and IGRA was not observed. When indeterminate IGRA results were excluded (n = 61), the agreement between TST and IGRA was κ = 0.30.
Conclusion
Although active tuberculosis was rare, screening results frequently affected prophylaxis initiation and treatment timing. Tuberculosis screening mainly functioned as a clinical decision-support tool rather than an infection detection method. Regular evaluation before and during biologic therapy remains necessary for safe management.
Zitieren
APA
Taskin, S. N., Karanfil, H. A., Mut, T. A., Oncel, E. B., Leblebicier, S. P., Kara, Y., & Yener, G. O. (2026). IMPACT OF TUBERCULOSIS SCREENING ON CLINICAL DECISION-MAKING IN PEDIATRIC PATIENTS RECEIVING BIOLOGIC THERAPY: A SINGLE-CENTER REAL-WORLD STUDY. Eskisehir Medical Journal, Eskisehir City Hospital. https://doi.org/10.48176/esmj.2026.256
Vancouver
Taskin SN, Karanfil HA, Mut TA, Oncel EB, Leblebicier SP, Kara Y, et al. IMPACT OF TUBERCULOSIS SCREENING ON CLINICAL DECISION-MAKING IN PEDIATRIC PATIENTS RECEIVING BIOLOGIC THERAPY: A SINGLE-CENTER REAL-WORLD STUDY. Eskisehir Medical Journal, Eskisehir City Hospital. 2026. doi:10.48176/esmj.2026.256
BibTeX
@article{Taskin2026,
author = {Taskin, Sema Nur and Karanfil, Hande Ayan and Mut, Tugce Arman and Oncel, Eda Boz and Leblebicier, Sule Pektas and Kara, Yalcin and Yener, Gulcin Otar},
title = {IMPACT OF TUBERCULOSIS SCREENING ON CLINICAL DECISION-MAKING IN PEDIATRIC PATIENTS RECEIVING BIOLOGIC THERAPY: A SINGLE-CENTER REAL-WORLD STUDY},
journal = {Eskisehir Medical Journal, Eskisehir City Hospital},
year = {2026},
doi = {10.48176/esmj.2026.256}
}
EUVIMED